Today on The Tape Reader: The highly anticipated $99 billion SpaceX lock-up expiration officially hits the market today, creating a massive liquidity test. Across the rest of the tape, software earnings are delivering brutal, binary outcomes, powering major breakouts like Shopify while punishing names like HubSpot and AppLovin.
Shopify (SHOP) shares surged 17.79% on Wednesday after reporting Q2 earnings and revenue that beat expectations. The move was amplified by a wave of bullish analyst actions, including a new 'Overweight' initiation from Morgan Stanley with a $192 price target and upgrades from Jefferies and Stifel. The stock broke out of a multi-week consolidation pattern on massive volume.
Why it matters
This is a textbook episodic pivot. The combination of a fundamental catalyst (strong earnings beat), a narrative shift (analysts highlighting AI Sidekick product potential), and technical confirmation (breakout on expanding volume) signals institutional accumulation. For swing traders, the key is to watch if the stock can hold the breakout level and consolidate its gains, which would suggest a new sustainable uptrend is in place.
Software stocks are seeing sharp, divergent reactions to earnings. HubSpot (HUBS) shares plunged 23.3% in Thursday's pre-market following corporate updates and a weaker outlook. Separately, AppLovin (APP) fell over 16% after Piper Sandler downgraded the stock to Neutral and slashed its price target from $665 to $385, citing a mixed Q2 report and weak Q3 guidance.
Why it matters
These moves highlight the market's brutal punishment for any signs of slowing growth or weak forward guidance in the software sector. For traders, these are prime short-side earnings gapper candidates. The key is to watch for failed bounces or breakdowns below pre-market lows on volume, which could signal continuation of the sell-off. The weakness in AppLovin could also create sympathy pressure on other ad-tech names.
Despite reporting Q2 revenue and EPS that beat estimates and raising Q3 guidance, AMD (AMD) shares fell roughly 9% in after-hours trading on Wednesday. The negative reaction was attributed to a gross margin miss (54% vs 56% consensus) and a Q3 revenue forecast of $13 billion that, while above consensus, failed to meet the market's most aggressive AI-growth expectations. The stock had rallied 7.7% into the print.
Why it matters
This is a classic 'sell the news' reaction where a strong report isn't strong enough. It underscores how sensitive high-multiple growth stocks are to whisper numbers and profitability metrics. The margin miss, tied to the ramp of its Helios AI platform, shows investors are scrutinizing the cost of competing with Nvidia. For traders, the key technical level to watch is the $460.55 support; a break below could signal further downside.
Eli Lilly (LLY) shares rose over 4% on Wednesday after the company reported Q2 results that significantly beat Wall Street estimates and raised its full-year revenue guidance. The outperformance was driven by massive demand for its GLP-1 obesity and diabetes drugs, Zepbound and Mounjaro, confirming the theme's continued market dominance.
Why it matters
Lilly's report reaffirms the GLP-1 category as one of the most powerful and durable growth themes in the market. The beat-and-raise serves as a strong catalyst, likely attracting further institutional capital into the space. For traders, LLY's strength provides a bullish read-through for other GLP-1 players and derivative plays in the supply chain. The post-earnings price action will be key to determining if this is a breakout to new highs or a 'sell the news' event after a strong run.
Uber (UBER) shares dropped 5.3% on Wednesday despite reporting Q2 EPS that met expectations. The sell-off was driven by the company's Q3 forecast for bookings and EPS, which trailed analyst estimates. Management also highlighted significant planned investments in its autonomous vehicle division.
Why it matters
This reaction demonstrates that forward guidance is paramount this earnings season. A weaker-than-expected outlook can completely negate in-line or even slightly better-than-expected current quarter results. The spending on autonomous vehicles highlights a conflict between long-term strategic investment and near-term profitability that is currently weighing on the stock, making it a candidate to watch for continued weakness.
Arista Networks (ANET) shares jumped over 11% in after-hours trading Tuesday following a strong Q2 earnings report that beat estimates on both revenue and profit. The company also provided a strong forecast, citing robust demand for its high-speed switching hardware driven by the AI infrastructure build-out. The stock gained another 3.97% during Wednesday's session.
Why it matters
Arista's results and guidance confirm its position as a key beneficiary of AI data center spending, separate from the GPU makers. The company's ability to gain market share and manage margins effectively in a tight supply chain environment signals strong operational execution. This makes ANET a core name to track within the AI infrastructure theme for relative strength and potential continuation plays.
The FDA issued a Complete Response Letter (CRL) on Thursday, declining to approve Vanda Pharmaceuticals' (VNDA) supplemental application for HETLIOZ as a treatment for jet lag disorder, citing issues with the company's study design. Vanda is disputing the agency's reasoning. In other FDA news, a decision is expected today on Moderna’s (MRNA) application for its mRNA-based seasonal flu vaccine, mFlusiva, which would be the first of its kind in the U.S.
Why it matters
These events highlight the binary nature of FDA catalysts. Vanda's rejection is a significant setback that will likely pressure the stock, creating a potential short-side catalyst. Conversely, Moderna's pending decision is a major binary event; an approval would open a multi-billion dollar market and validate its mRNA platform beyond COVID, likely causing a significant stock move. Traders should be watching MRNA for unusual volume and price action ahead of the expected announcement.
Amgen (AMGN) received a significant FDA label expansion on Wednesday for its cholesterol drug, Repatha. The drug is now approved for primary prevention of cardiovascular events in at-risk adults, considerably broadening its eligible patient population beyond its previous, more limited indication for secondary prevention.
Why it matters
This FDA approval is a major commercial catalyst that substantially expands the addressable market for Repatha, providing Amgen with a strong near-term revenue growth driver. This news can act as an episodic pivot, shifting the fundamental outlook for the product line and potentially leading to a re-rating of the stock as analysts update their models to account for the larger market opportunity.
The $99 billion SpaceX (SPCX) lock-up expiration we've been tracking for weeks arrives today, allowing insiders to begin selling the 911.5 million shares now eligible for the open market. This massive supply event hits right after the company's first public earnings report, where high AI-related capital expenditures already pressured the stock, setting up a severe test of market appetite against a wall of potential selling.
Why it matters
This is the climax of the parabolic short setup we've followed leading into this date. With short interest swelling to a $25 billion notional value ahead of today, the sheer size of the share unlock relative to the initial low float creates a severe supply/demand imbalance. The key dynamic remains how the market absorbs this new supply; failure to find sufficient buyers could break the stock below its recent $108 support and lead to a sustained downward trend.
U.S. stock futures are mixed heading into Thursday's open, with the Dow and S&P 500 pointing higher while the Nasdaq 100 slips. Crude oil prices continue to ease—following the 10% plunge we've tracked over the past two sessions—on reports of progress in an Oman-brokered diplomatic deal to reopen the Strait of Hormuz, further reducing inflation fears. Key levels to watch are the bull/bear pivots in SPY and QQQ, with traders also bracing for today's SpaceX lockup and weekly jobless claims data.
Why it matters
This provides a tactical snapshot for the opening drive. The mixed futures suggest a potential continuation of the rotation out of tech. The easing oil prices are a macro tailwind, but the session will likely be dictated by the market's reaction to the SpaceX supply event and key technical levels in the major indices. Watching how SPY and QQQ react at their defined pivots will be critical for intraday positioning.
Guidance and Margins Punish Earnings Gappers Several companies including HubSpot, AppLovin, and Uber are trading sharply lower despite some meeting headline expectations. The market is penalizing weak forward guidance, rising capital expenditures, and margin compression, underscoring a focus on profitability and sustainable growth over top-line beats.
SpaceX Faces Massive Supply Overhang The first major lock-up expiration for SpaceX arrives today, releasing an estimated 911 million shares. This creates a massive potential supply imbalance for a stock that has already been under pressure, setting up a critical test of institutional demand against heavy insider selling pressure.
Shopify Stages Major Episodic Pivot A powerful combination of strong Q2 results, bullish guidance, and a wave of tier-1 analyst upgrades has propelled Shopify stock over 17%. This move represents a classic episodic pivot, breaking out of a multi-month base on high volume as the narrative shifts to AI integration and sustained e-commerce growth.
Biotech Catalysts Create Binary Outcomes FDA decisions continue to drive significant, often binary, moves in the biotech sector. Vanda Pharmaceuticals was rejected for its jet lag treatment, while Moderna awaits a key decision on its flu vaccine. Meanwhile, Arrowhead secured a Priority Review Voucher, accelerating a potential drug launch.
Sector Rotation Continues, But Internals Mixed While the Dow Jones hits new highs, the Nasdaq is showing signs of weakness, highlighting a rotation out of mega-cap tech and into other sectors. Market breadth remains constructive, with money flowing into healthcare and materials, but the divergence between indices warrants caution.
What to Expect
2026-08-07—July Non-Farm Payrolls (NFP) report to be released, a key catalyst for Fed policy expectations.
2026-08-12—July Consumer Price Index (CPI) data to be released.
2026-09-16—Next FOMC meeting and interest rate decision.
2026-09-22—PDUFA date for Intra-Cellular Therapies' zilganersen for Alexander Disease.
2026-09-30—PDUFA date for Scholar Rock's apitegromab for spinal muscular atrophy.
How We Built This Briefing
Every story, researched.
Every story verified across multiple sources before publication.
🔍
Scanned
Across multiple search engines and news databases
619
📖
Read in full
Every article opened, read, and evaluated
185
⭐
Published today
Ranked by importance and verified across sources
10
— The Tape Reader
🎙 Listen as a podcast
Subscribe in your favorite podcast app to get each new briefing delivered automatically as audio.
Apple Podcasts
Library tab → ••• menu → Follow a Show by URL → paste